Compare FCCO & CUVL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FCCO | CUVL |
|---|---|---|
| Founded | 1994 | N/A |
| Country | United States | Australia |
| Employees | N/A | 16 |
| Industry | Major Banks | Miscellaneous |
| Sector | Finance | Miscellaneous |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 321.1M | 374.2M |
| IPO Year | 2012 | N/A |
| Metric | FCCO | CUVL |
|---|---|---|
| Price | $33.79 | $6.18 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 40.0K | 6.2K |
| Earning Date | 04-22-2026 | N/A |
| Dividend Yield | ★ 2.16% | N/A |
| EPS Growth | ★ 36.46 | N/A |
| EPS | ★ 1.39 | N/A |
| Revenue | ★ $922,000.00 | N/A |
| Revenue This Year | $30.67 | N/A |
| Revenue Next Year | $5.87 | N/A |
| P/E Ratio | $24.03 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $25.92 | $6.20 |
| 52 Week High | $35.74 | $8.20 |
| Indicator | FCCO | CUVL |
|---|---|---|
| Relative Strength Index (RSI) | 47.97 | 39.75 |
| Support Level | $32.35 | N/A |
| Resistance Level | $33.70 | $7.04 |
| Average True Range (ATR) | 0.88 | 0.34 |
| MACD | -0.16 | -0.02 |
| Stochastic Oscillator | 33.47 | 0.00 |
First Community Corp is a bank holding company. Along with its subsidiaries, it provides various banking products and services for professionals and small and medium-sized businesses, including consumer and commercial banking, mortgage, brokerage and investment, online banking, and insurance services. The company offers checking, savings, money market, individual retirement, and certificates of deposit accounts, and its lending lines include consumer loans, real estate loans, home improvement loans, home loans, flex loans, construction loans, agricultural loans, and others. The company's reportable segments are: Commercial and Retail Banking, which derives maximum revenue; Mortgage Banking; Investment Advisory and Non-Deposit; and Corporate.
Clinuvel distributes a single product, Scenesse, the only approved treatment for phototoxic reactions specifically associated with a rare genetic disease called erythropoietic protoporphyria. EPP causes extreme pain or burns from brief exposure to light, affecting a patient's quality of life. Scenesse is a patented dissolvable implant, comparable in size with a rice grain, injected underneath the skin roughly every three months for ongoing protection. The implant controls the release of a synthetic drug which promotes the production of more melanin, thereby reducing pain and increasing tolerance for light exposure. The majority of Clinuvel's earnings stem from Europe and the US.